A randomized double-blind cross-over patient preference study of pazopanib versus sunitinib in treatment-naive locally advanced or metastatic renal cell carcinoma (mRCC).

2010 
TPS237 Background: Angiogenesis inhibitors have demonstrated significant clinical efficacy in mRCC. Pazopanib and sunitinib are both oral tyrosine kinase inhibitors primarily of VEGFR (−1, −2, and −3), PDGFR (-a and -b) and c-Kit. Pazopanib has a more selective kinase specificity profile compared to sunitinib and has demonstrated low rates of fatigue, hand foot syndrome and mucositis/stomatitis. There is an ongoing phase III head to head study of pazopanib vs. sunitinib in treatment naive mRCC patients (pts). The outcomes of cancer therapy are traditionally evaluated using RECIST response and survival criteria. There is increasing emphasis on assessment of health related quality of life (HRQoL) particularly relevant to tolerability of agents. However, HRQoL questionnaires might not reflect the pt preference. Studies have shown an association between toxicity/intolerability and a response on HRQoL, suggesting that pt preference is a legitimate and useful endpoint. This study evaluates whether tolerability ...
    • Correction
    • Source
    • Cite
    • Save
    • Machine Reading By IdeaReader
    0
    References
    5
    Citations
    NaN
    KQI
    []